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Abstract
Aims Metformin is the most widely used oral anti-diabetes agent and has considerable benefits over other therapies, yet
20–30% of people develop gastrointestinal side effects, and 5% are unable to tolerate metformin due to the severity of
these side effects. The mechanism for gastrointestinal side effects and their considerable inter-individual variability is
unclear. We have recently shown the association between organic cation transporter 1 (OCT1) variants and severe
intolerance to metformin in people with Type 2 diabetes. The aim of this study was to explore the association of OCT1
reduced-function polymorphisms with common metformin-induced gastrointestinal side effects in Type 2 diabetes.
Methods This prospective observational cohort study included 92 patients with newly diagnosed Type 2 diabetes,
incident users of metformin. Patients were genotyped for two common loss-of-function variants in the OCT1 gene
(SLC22A1): R61C (rs12208357) and M420del (rs72552763). The association of OCT1 reduced-function alleles with
gastrointestinal side effects was analysed using logistic regression.
Results Forty-three patients (47%) experienced gastrointestinal adverse effects in the first 6 months of metformin
treatment. Interestingly, the number of OCT1 reduced-function alleles was significantly associated with over two-fold
higher odds of the common metformin-induced gastrointestinal side effects (odds ratio = 2.31, 95% confidence interval
1.07–5.01, P = 0.034).
Conclusions In conclusion, we showed for the first time the association between OCT1 variants and common
metformin-induced gastrointestinal side effects. These results confirm recent findings related to the role of OCT1 in
severe metformin intolerance, and suggest that high inter-individual variability in mild/moderate and severe
gastrointestinal intolerance share a common underlying mechanism. These data could contribute to more personalized
and safer metformin treatment.
Diabet. Med. 33, 511–514 (2016)
Introduction
Metformin is the first-line drug for treatment of Type 2
diabetes [1], and the most widely used oral anti-diabetes
agent. It has considerable advantages over other Type 2
diabetes therapies, including low risk of hypoglycaemia,
weight neutrality, low cost and possible cardiovascular
benefits [1]. However, 20–30% of people treated with
metformin develop gastrointestinal side effects, and 5% are
unable to tolerate metformin due to the severity of these side
effects [2]. The mechanism behind gastrointestinal side
effects and their considerable inter-individual variability is
not known. We recently reported the first study of the genetic
and phenotypic determinants of severe intolerance to met-
formin in a large cohort of people with Type 2 diabetes [3].
Reduced-function alleles of organic cation transporter 1
(OCT1), and the concomitant use of medications known to
inhibit OCT1 activity, were identified as risk factors for
metformin intolerance [3]. However, in the reported
research, a proxy phenotype for metformin gastrointestinal
intolerance was established based upon prescribing patterns,
namely the discontinuation of metformin and switching to
another oral hypoglycaemic agent in the first months of
metformin treatment. In this study, we aimed to explore the
association between OCT1 reduced-function variants and
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common metformin gastrointestinal side effects in a prospec-
tively recruited cohort of patients with newly diagnosed
Type 2 diabetes, incident users of metformin.
Patients and methods
This prospective observational study included patients with
newly diagnosed Type 2 diabetes who were prescribed
metformin as their initial hypoglycaemic therapy. Patients
were recruited from the Clinic for Endocrinology and
Diabetes, University Clinical Centre of Sarajevo. The
research was carried out in accordance with the ethics
recommendations and practices of the University Clinical
Centre of Sarajevo, and complied with ethics principles
outlined in the Declaration of Helsinki. The study was
approved by Ethics Committee of the International Univer-
sity of Sarajevo, and each patient gave written informed
consent.
Ninety-two patients with a Type 2 diabetes diagnosis after
the age of 35 years were included in the study. Patients with
chronic gastrointestinal diseases, including chronic liver
disease, cholelithiasis, chronic pancreatitis, inflammatory
bowel disease and gastroduodenal ulcer, chronic kidney
disease, endocrine disorders, infection and hormonal therapy
were excluded. Patients were monitored during the first
6 months of metformin treatment. The gastrointestinal side
effects of metformin were defined as the presence of any of
the following symptoms during metformin therapy: bloating,
abdominal pain, nausea, diarrhoea, vomiting, and anorexia,
in the absence of any acute gastrointestinal disease.
Patients were genotyped afterwards for two common loss-
of-function variants in the OCT1 gene (SLC22A1): R61C
(rs12208357) and M420del (rs72552763), using TaqMan
genotyping assays (Applied Biosystems, Foster City, CA,
USA). Both variants were in line with the Hardy–Weinberg
equilibrium (P > 0.05).
Differences in the categorical variables were tested using
the v2-test, and differences in continuous variables using the
t-test (variables with normal distribution) or Mann–Whitney
U–test (variables with non-normal distribution). R61C and
M420del variants were analysed together, according to the
number of haplotypes carrying reduced-function alleles: 0, 1
or 2 (OCT1 combined genotype). Haplotype analysis was
performed using PLINK software (http://pngu.mgh.har-
vard.edu/purcell/plink/) [4]. The OCT1 combined genotype
frequencies between the two groups were compared using the
exact Cochran–Armitage trend test (additive model). The
association of OCT1 diplotypes with gastrointestinal side
effects was analysed using logistic regression, with age, sex,
weight and concomitant use of OCT1-inhibiting medications
[5] as covariates [3]. Statistical analyses were performed with
SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Of a total of 92 patients enrolled in the study, 43 experienced
gastrointestinal side effects. Baseline characteristics for the
patients are shown in Table 1. Patients with metformin-
induced side effects were more commonly women
(P = 0.004), and accordingly, had lower body weight
(P = 0.007), higher HDL-cholesterol (P = 0.002) and lower
creatinine levels (P = 0.001) than the group without gas-
trointestinal symptoms at the beginning of metformin ther-
apy (Table 1).
Haplotype and diplotype frequencies for R61C and
M420del variants are shown in Tables S1–S2. The two
OCT1 variants occurred only on the wild-type allele of each
other (D0 = 1.00, r2 = 0.02), in line with other studies in
Caucasians [3]. As shown in Table S2, the number of
reduced-function haplotypes in each patient could be char-
acterized by the total numbers of variant alleles in R61C and
M420del (OCT1 combined genotype). The numbers of
patients with 0, 1 or 2 reduced-function alleles (the OCT1
combined genotype frequencies) are shown in Table 1. There
was a significant difference in the combined genotype
frequencies between the two groups (P = 0.048).
The results of the logistic regression analysis model are
presented in Table 2. Although individual variants were not
associated with the occurrence of side effects in the multi-
variate model (data not shown), the number of OCT1
reduced-function alleles was significantly associated with
more than two-fold higher odds of metformin side effects
[Table 2, odds ratio (OR) = 2.31, 95% confidence interval
(CI) 1.07–5.01, P = 0.034]. Female sex and lower weight
showed a trend of association with the incidence of
gastrointestinal side effects, without reaching statistical
significance (Table 2).
Discussion
Metformin is used by over 120 million people worldwide,
and considering the high prevalence of metformin-induced
gastrointestinal distress, millions of people are suffering
from these adverse effects during metformin treatment.
These symptoms negatively affect their quality of life and
may result in suboptimal drug dosage and non-adherence
What’s new?
• The mechanism of high inter-individual variability in
gastrointestinal side effects associated with metformin
treatment is unknown.
• We show for the first time the association between
organic cation transporter 1 reduced-function variants
and common metformin-induced gastrointestinal side
effects.
• These results might contribute to more personalized
and safer treatment with metformin.
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[6]. Although different hypotheses have been suggested, the
pathophysiology of metformin-induced gastrointestinal side
effects is not clear, and data are lacking to explain the high
inter-individual variability [7]. In this prospective study, we
found for a first time a significant association between the
number of OCT1 reduced-function alleles and common
gastrointestinal adverse effects to metformin. These results
are in accordance with earlier findings obtained in the large
GoDARTS cohort in which severe gastrointestinal intoler-
ance to metformin was investigated [3]. However, in the
GoDARTS study, only individuals carrying two deficient
OCT1 alleles (recessive model) had higher odds of severe
intolerance leading to discontinuation of therapy compared
with individuals with one or no deficient alleles. Interest-
ingly, in the current study, the number of deficient alleles
(additive model) was associated with common metformin
gastrointestinal side effects. Thus, our results suggest that
the high inter-individual variability seen in mild/moderate,
as well as severe gastrointestinal intolerance shares a
common underlying mechanism despite the considerably
different intensity and duration of gastrointestinal symp-
toms.
Furthermore, female sex and lower body weight showed a
trend of association with side effects, in accordance with the
GoDARTS findings [3]. However, contrary to our earlier
study [3], age and the concomitant use of OCT1-inhibiting
drugs had no significant effect on the incidence of side effects.
A reason for this discrepancy might be difference in the
studied phenotypes between the two studies (common vs.
severe intolerance), or perhaps the small sample size in the
current study.
Our results are in contrast with a previous study [8]
demonstrating significant associations of the OCT1 variants
M408V and the 8-bp insertion rs36056065 with the presence
of common metformin gastrointestinal adverse effects,
whereas R61C and M420del or OCT1 haplotypes had no
effect. However, M408V does not alter the uptake of
metformin in vitro [9], and the function of rs36056065 is
unknown. Also, contrary to our results, the prevalence of
side effects was correlated positively with age [8], in line with
the GoDARTS results [3]. However, both previous studies
Table 1 Baseline characteristics of patients with and without gastrointestinal side effects
Group without gastrointestinal
side effects (n = 49)
Group with gastrointestinal
side effects (n = 43) P
Age (years) 58.8  8.4 57.1  9.5 0.365
Women/men (% women) 22/27 (44.9) 32/11 (74.4) 0.004
Weight (kg) 93.7  15.8 85.2  13.8 0.007
BMI (kg/m2) 31.7  4.2 30.4  4.3 0.128
Fasting plasma glucose (mmol/l) 8.0 (7.5–9.2) 8.2 (7.5–9.2) 0.573
Fasting plasma insulin (pmol/l) 95.0 (57.0–154.0) 120.5 (70.0–186.0) 0.246
HOMA-IR* 4.4 (2.9–8.1) 6.1 (3.7–8.9) 0.198
HbA1c (mmol/l) 56 (51–63) 58 (53–66) 0.376
HbA1c (%) 7.3 (6.8–7.9) 7.5 (7.0–8.2)
Total cholesterol (mmol/l) 5.2  1.3 5.3  1.2 0.690
HDL-cholesterol (mmol/l) 1.02  0.23 1.18  0.25 0.002
LDL-cholesterol (mmol/l) 3.27  1.27 3.10  1.09 0.523
Triglycerides (mmol/l) 1.93 (1.53–3.13) 2.22 (1.40–3.18) 0.997
Creatinine (lmol/l) 84.1  17.8 71.9  16.2 0.001
Creatinine clearance (ml/min)† 109.1  28.9 109.0  31.8 0.983
Metformin daily dose (mg) 1000 (821–1500) 1000 (960–1700) 0.492
Use of OCT1 inhibiting drugs‡ 6 (14.0%) 8 (16.3%) 0.752
Number of OCT1 reduced-function alleles (0/1/2)§ 30/17/2 (61.2%/34.7%/4.1%) 18/20/5 (41.9%/46.5%/11.6%) 0.048¶
Data are presented as means  SD, medians (interquartile range) or numbers (percentages).
*The homeostasis model assessment insulin resistance index was calculated using the formula: fasting insulin (pmol/l) 9 fasting glucose
(mmol/l)/156.26.
†Creatinine clearance was estimated using the Cockcroft–Gault formula.
‡Number of individuals concomitantly treated with OCT1 inhibiting drugs, including proton pump inhibitors, clopidogrel, doxazosin,
verapamil, tramadol and citalopram [3,5].
§Data are presented as numbers of individuals (percentages).
¶Significance of test for comparison of combined genotype frequencies between the two groups under the additive model.
Table 2 Association of OCT1 combined genotype with metformin
gastrointestinal side effects – logistic regression model
OR (95% CI) P
Age 0.96 (0.91–1.01) 0.121
Sex (Women vs Men) 2.49 (0.91–6.82) 0.076
Weight 0.97 (0.94–1.00) 0.074
Use of OCT1-inhibiting drugs 0.93 (0.27–3.19) 0.912
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also included patients with a longer duration of Type 2
diabetes treated with other anti-diabetes drugs in addition to
metformin, whereas in the current study, only patients with
newly diagnosed Type 2 diabetes and metformin prescribed
as their initial Type 2 diabetes therapy were included. This
might explain the similar age between patients with and
without gastrointestinal adverse effects.
The mechanism behind the association of OCT1 reduced
transport with increased metformin side effects is not clear.
It has been suggested that gastrointestinal symptoms are due
to high local concentrations of metformin in the intestine
[10]. Because OCT1 is expressed in the membranes of
enterocytes [11,12], a change in its activity might affect local
metformin concentrations in the gut, possibly leading to
changes in incretins, ghrelin, bile acids or serotonin balance
[7].
The main limitation of our study is its limited power. This
might be the reason for not detecting the effect of OCT1-
inhibiting drugs on common metformin side effects. Future
studies in larger cohorts are needed to explore these possible
interactions and to confirm our findings.
In conclusion, we showed for the first time the association
between OCT1 reduced-function alleles and the incidence of
common metformin-induced gastrointestinal side effects in
patients with Type 2 diabetes. Importantly, this study
confirms recent findings related to the role of OCT1 in
severe metformin intolerance, further supporting the role of
OCT1 variants in gastrointestinal side effects following
metformin treatment.
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